Zacks Research Has Strong Estimate for TEVA FY2026 Earnings

Key Points

• Zacks Research has raised its FY2026 earnings estimate for Teva Pharmaceutical Industries to $2.57 per share, slightly up from a previous forecast of $2.56. This is above the current consensus estimate of $2.50.
• Teva's recent earnings report showed a Q2 EPS of $0.66, surpassing the consensus estimate of $0.64, despite experiencing a negative net margin of 0.95%.
• UBS Group and JPMorgan Chase have both raised their price targets for Teva to $26.00, with multiple analysts giving it a consensus rating of "Buy."

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) - Investment analysts at Zacks Research lifted their FY2026 earnings estimates for Teva Pharmaceutical Industries in a report released on Tuesday, October 7th. Zacks Research analyst Team now expects that the company will post earnings per share of $2.57 for the year, up from their previous forecast of $2.56. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' Q4 2026 earnings at $0.72 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The company had revenue of $4.18 billion during the quarter, compared to analysts' expectations of $4.34 billion. During the same period last year, the company posted $0.61 earnings per share. The business's revenue for the quarter was up .3% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS.

Other equities analysts have also recently issued research reports about the company. UBS Group lifted their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday, September 24th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Finally, JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company an "overweight" rating in a research note on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $25.57.

Teva Pharmaceutical Industries Trading Up 0.7%

NYSE:TEVA opened at $20.22 on Thursday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. Teva Pharmaceutical Industries has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The stock's 50-day moving average is $18.33 and its two-hundred day moving average is $16.89. The stock has a market cap of $23.19 billion, a PE ratio of -126.38, a price-to-earnings-growth ratio of 1.17 and a beta of 0.71.

Insider Buying and Selling

In other news, insider Eric A. Hughes sold 52,742 shares of the company's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Placid Jover sold 6,053 shares of the company's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the transaction, the insider owned 6,774 shares of the company's stock, valued at approximately $102,693.84. This trade represents a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.49% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of TEVA. GAMMA Investing LLC raised its stake in shares of Teva Pharmaceutical Industries by 804.7% in the first quarter. GAMMA Investing LLC now owns 67,474 shares of the company's stock valued at $1,037,000 after purchasing an additional 60,016 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Teva Pharmaceutical Industries by 0.8% in the first quarter. Rhumbline Advisers now owns 281,062 shares of the company's stock valued at $4,320,000 after purchasing an additional 2,128 shares in the last quarter. Yousif Capital Management LLC raised its stake in shares of Teva Pharmaceutical Industries by 1.9% in the first quarter. Yousif Capital Management LLC now owns 55,986 shares of the company's stock valued at $861,000 after purchasing an additional 1,033 shares in the last quarter. Handelsbanken Fonder AB acquired a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at $243,000. Finally, Assenagon Asset Management S.A. raised its stake in shares of Teva Pharmaceutical Industries by 416.0% in the first quarter. Assenagon Asset Management S.A. now owns 5,983,928 shares of the company's stock valued at $91,973,000 after purchasing an additional 4,824,247 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.